Harry Yan and Weiman Gao have bestowed $1 million on the Baker Institute of Public Policy to establish the interdisciplinary Neuro-Policy Program. Photo via rice.edu

A big donation to Rice University will soon help researchers better understand the workings of the human brain.

Harry Yan and Weiman Gao have bestowed $1 million on the Baker Institute of Public Policy to establish the interdisciplinary Neuro-Policy Program.

Neuro-policy is a newer field that explores how brain health and function can help to fuel economic growth.

“The Neuro-Policy Program is at the forefront of pioneering data analysis, empirical research and policy application,” says Harris Eyre, the lead for the program, as well as a senior fellow in brain health at the Baker Institute, in a news release. “Investing in evidence-based strategies for prevention, diagnosis and treatment can reduce brain and mental health disparities, optimize cognitive development and performance and foster innovation to build more resilient communities.”

Eyre describes the collective value of the human brain as “brain capital.” That’s because brains that are suffering from any number of neurodegenerative or mental health disorders (including depression, anxiety, brain injury and Alzheimer’s disease) have actually taken a toll on the U.S. economy, Eyre explains.

The Neuro-Policy Program seeks to improve brain performance, and consequently enhance economic growth, national security, and our overall standing as a nation of healthy brains. The program’s primary projects include establishing a task force to advise Texas “brain and mind” legislative efforts as well as a Texas Brain Capital Dashboard, collaborating on Texas Forward (Texas Brain Health Plan) with the UT Dallas Center for BrainHealth, thereby working toward U.S. brain capital policy and investment advances. These projects are expected to yield deliverables as early as 2026.

“The Neuro-Policy Program aims to leverage the university’s proximity to the Texas Medical Center and the institute’s strong connections to state and federal policymakers. This is an important yet underrepresented area of research that Houston is poised to lead,” says David Satterfield, the director of the Baker Institute.

Yan and Gao said in a press release that they were inspired to gift the grant funds to Eyre and his research after attending a March 28 Baker Institute event on brain health that featured U.S. Rep. Morgan Luttrell, a co-chair of the Congressional Neuroscience Caucus.

"We are honored to support Dr. Harris Eyre and the Neuro-Policy program he leads. Dr. Eyre’s work has greatly impressed us, highlighting the critical importance of brain health in our society today,” say Yan and Gao. “We hope our contribution can inspire further support and advocacy in the field, helping individuals lead healthier lives through a comprehensive approach to prevention.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.